Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,300 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05183035 | Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | recruiting | Phase 3 | 130 | PedAL BCU, LLCOTHER | 20 | Aug 24, 2026 | clinicaltrials |
| NCT05388370 | PASS of Paediatric Patients Initiating Selumetinib | active not recruiting | — | 124 | AstraZenecaINDUSTRY | 10 | Aug 24, 2026 | clinicaltrials |
| NCT06084481 |
| Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 |
| recruiting |
| Phase 1 |
| 325 |
| AbbVieINDUSTRY |
| 8 |
| Aug 24, 2026 |
| clinicaltrials |
| NCT05458297 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | active not recruiting | Phase 2 | 189 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Aug 21, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT06499285 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | recruiting | Phase 3 | 225 | TakedaINDUSTRY | 26 | Aug 21, 2026 | clinicaltrials |
| NCT07209111 | A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)(KANDLELIT-014) | recruiting | Phase 2 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Aug 21, 2026 | clinicaltrials |
| NCT02386800 | CINC424A2X01B Rollover Protocol | active not recruiting | Phase 4 | 279 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 20, 2026 | clinicaltrials |
| NCT03682068 | Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer(NILE) | active not recruiting | Phase 3 | 1,246 | AstraZenecaINDUSTRY | 22 | Aug 20, 2026 | clinicaltrials |
| NCT04667234 | Expanded Access of Sotorasib | no longer available | — | — | AmgenINDUSTRY | 6 | Aug 20, 2026 | clinicaltrials |
| NCT04886804 | Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | active not recruiting | Phase 1 | 554 | Boehringer IngelheimINDUSTRY | 18 | Aug 20, 2026 | clinicaltrials |
| NCT04936308 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent(SOLSTICE) | completed | Phase 3 | 453 | Janssen Research & Development, LLCINDUSTRY | 14 | Aug 20, 2026 | clinicaltrials |
| NCT05468697 | A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) | active not recruiting | Phase 1 / Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Aug 20, 2026 | clinicaltrials |
| NCT05614739 | FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3(FORAGER-1) | recruiting | Phase 1 | 677 | Eli Lilly and CompanyINDUSTRY | 14 | Aug 20, 2026 | clinicaltrials |
| NCT03007147 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 352 | Children's Oncology GroupNETWORK | 19 | Aug 19, 2026 | clinicaltrials |
| NCT05142696 | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT05714839 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments(DynaMMic-1) | recruiting | Phase 1 / Phase 2 | 123 | GlaxoSmithKlineINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT05774951 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy(CAMBRIA-1) | recruiting | Phase 3 | 4,300 | AstraZenecaINDUSTRY | 39 | Aug 19, 2026 | clinicaltrials |
| NCT06194448 | To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations(NEOLA) | active not recruiting | Phase 2 | 76 | AstraZenecaINDUSTRY | 9 | Aug 19, 2026 | clinicaltrials |
| NCT06556563 | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma(EF-41) | recruiting | Phase 3 | 741 | NovoCure GmbHINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT03106779 | Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | completed | Phase 3 | 233 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 18, 2026 | clinicaltrials |
| NCT06731907 | A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) | recruiting | Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Aug 18, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT05169515 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 121 | Hoffmann-La RocheINDUSTRY | 5 | Aug 17, 2026 | clinicaltrials |
| NCT05254743 | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN-CLL-314) | recruiting | Phase 3 | 737 | Loxo Oncology, Inc.INDUSTRY | 23 | Aug 17, 2026 | clinicaltrials |
| NCT03334708 | A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma | recruiting | — | 120 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Aug 14, 2026 | clinicaltrials |
| NCT03742895 | Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) | active not recruiting | Phase 2 | 329 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Aug 14, 2026 | clinicaltrials |
| NCT05853575 | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | active not recruiting | Phase 2 | 200 | Mirati Therapeutics Inc.INDUSTRY | 18 | Aug 14, 2026 | clinicaltrials |
| NCT06074588 | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | active not recruiting | Phase 3 | 556 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Aug 14, 2026 | clinicaltrials |
| NCT06149286 | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma(OLYMPIA-5) | recruiting | Phase 3 | 580 | Regeneron PharmaceuticalsINDUSTRY | 18 | Aug 14, 2026 | clinicaltrials |
| NCT04924101 | Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) | completed | Phase 2 | 122 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Aug 13, 2026 | clinicaltrials |
| NCT05675449 | A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma(MagnetisMM-20) | active not recruiting | Phase 1 | 59 | PfizerINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT06167317 | Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 278 | Gilead SciencesINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT01698905 | Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)(ENESTop) | completed | Phase 2 | 163 | Novartis PharmaceuticalsINDUSTRY | 18 | Aug 12, 2026 | clinicaltrials |
| NCT06517758 | A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | active not recruiting | Phase 3 | 146 | Novartis PharmaceuticalsINDUSTRY | 18 | Aug 12, 2026 | clinicaltrials |
| NCT06759649 | A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies | recruiting | Phase 1 | 200 | Compugen LtdINDUSTRY | 2 | Aug 12, 2026 | clinicaltrials |
| NCT06801834 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer(EVOKE-SCLC-04) | recruiting | Phase 3 | 695 | Gilead SciencesINDUSTRY | 23 | Aug 12, 2026 | clinicaltrials |
| NCT01437787 | Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis(JAKARTA) | terminated | Phase 3 | 289 | Bristol-Myers SquibbINDUSTRY | 25 | Aug 11, 2026 | clinicaltrials |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma(FIGHT-302) | terminated | Phase 3 | 167 | Incyte CorporationINDUSTRY | 19 | Aug 11, 2026 | clinicaltrials |
| NCT04790474 | Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib(IPoD-790) | active not recruiting | Phase 2 | 61 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05646836 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma | active not recruiting | Phase 1 | 90 | Genentech, Inc.INDUSTRY | 7 | Aug 11, 2026 | clinicaltrials |
| NCT05837884 | Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population | recruiting | — | 2,000 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Aug 11, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials